SNIFF Multi-Device Study 2

NCT04199767 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Mild Cognitive Impairment
Cognitive Impairment

Interventions

DRUG: 20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
DRUG: 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)

Sponsor

Wake Forest University Health Sciences